Next Article in Journal
Innovative Technologies for Reverse Total Shoulder Arthroplasty in Australia: Market Access Challenges and Implications for Patients, Decision-Makers, and Manufacturers
Previous Article in Journal
Machine-Learning Prediction for Hospital Length of Stay Using a French Medico-Administrative Database
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 11
Issue 1
10.1080/20016689.2022.2154418
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cost-Effectiveness of Infant Hypoallergenic Formulas to Manage Cow’s Milk Protein Allergy in France

by
Ana Teresa Paquete
1,
Rui Martins
1,2,
Mark P. Connolly
1,2,*,
Marie Meulle
3,
Nítida Pastor
4,
Grégoire Benoist
5 and
Patrick Tounian
6
1
Health Economics Unit, Health Economics Consultants, Global Market Access Solutions, Saint-Prex, Switzerland
2
Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
3
Benckiser Healthcare France, Reckitt Benckiser, Paris, France
4
Medical and Scientific Affairs, Nutrition, Reckitt Benckiser, Evansville, IN 47721, USA
5
Department of Pediatrics, CHU Ambroise Paré, APHP, 92100 Boulogne-Billancourt, France
6
Pediatric Nutrition and Gastroenterology Department, Trousseau Hospital, APHP, Sorbonne University, Paris, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2023, 11(1), 2154418; https://doi.org/10.1080/20016689.2022.2154418
Submission received: 25 May 2022 / Revised: 29 November 2022 / Accepted: 29 November 2022 / Published: 10 December 2022

Abstract

Background: Clinician’s choice of hypoallergenic formulas in the first-line management of cow’s milk protein allergy (CMPA) should be informed by evidence on clinical efficacy and cost-effectiveness. Objective: We compare the cost-effectiveness of amino acid-based formula (AAF), extensively hydrolyzed casein formula with Lactobacillus rhamnosus Gorbach Goldin (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), and rice hydrolyzed formula (RHF) in non-breastfed children in France. Methods: Immunotolerance and atopic manifestations’ prevalence were based on a prospective non-randomized study with a 36-month follow-up. Resource utilization was sourced from a survey of French clinicians, and unit costs were based on national data. Costs and health consequences were discounted at 2.5% annually. Results were reported using the Collective and French National Health Insurance perspectives. Results: Children receiving EHCF+LGG were predicted to require less healthcare resources, given their reduced prevalence of CMPA symptoms at 3 years. In the base case, EHCF+LGG led to savings of at least €674 per child compared to AAF, EHWF, and RHF at 3 years, from both perspectives. Nutrition had the highest economic burden in CMPA, driven by hypoallergenic formulas and dietetic replacements costs. Results were robust to one-way and probabilistic sensitivity analyses. Conclusions: EHCF+LGG was associated with more symptom-free time, higher immune tolerance, and lower costs.
Keywords: cow’s milk protein allergy; cost-effectiveness analysis; child nutrition sciences; milk substitutes; France cow’s milk protein allergy; cost-effectiveness analysis; child nutrition sciences; milk substitutes; France

Share and Cite

MDPI and ACS Style

Paquete, A.T.; Martins, R.; Connolly, M.P.; Meulle, M.; Pastor, N.; Benoist, G.; Tounian, P. Cost-Effectiveness of Infant Hypoallergenic Formulas to Manage Cow’s Milk Protein Allergy in France. J. Mark. Access Health Policy 2023, 11, 2154418. https://doi.org/10.1080/20016689.2022.2154418

AMA Style

Paquete AT, Martins R, Connolly MP, Meulle M, Pastor N, Benoist G, Tounian P. Cost-Effectiveness of Infant Hypoallergenic Formulas to Manage Cow’s Milk Protein Allergy in France. Journal of Market Access & Health Policy. 2023; 11(1):2154418. https://doi.org/10.1080/20016689.2022.2154418

Chicago/Turabian Style

Paquete, Ana Teresa, Rui Martins, Mark P. Connolly, Marie Meulle, Nítida Pastor, Grégoire Benoist, and Patrick Tounian. 2023. "Cost-Effectiveness of Infant Hypoallergenic Formulas to Manage Cow’s Milk Protein Allergy in France" Journal of Market Access & Health Policy 11, no. 1: 2154418. https://doi.org/10.1080/20016689.2022.2154418

APA Style

Paquete, A. T., Martins, R., Connolly, M. P., Meulle, M., Pastor, N., Benoist, G., & Tounian, P. (2023). Cost-Effectiveness of Infant Hypoallergenic Formulas to Manage Cow’s Milk Protein Allergy in France. Journal of Market Access & Health Policy, 11(1), 2154418. https://doi.org/10.1080/20016689.2022.2154418

Article Metrics

Back to TopTop